US FDA approves French drugmaker Ipsen’s rare bone disorder drug
By Bhanvi Satija and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration (FDA) on Wednesday approved French drugmaker Ipsen’s drug for a rare bone disorder, making it the first treatment available to patients with the condition that causes abnormal bone growth. The company said its drug, Sohonos, was approved in adults and pediatric patients…
